CA2640743C - Pharmaceutical composition of microspheres for preventing diabetic limb amputation - Google Patents

Pharmaceutical composition of microspheres for preventing diabetic limb amputation Download PDF

Info

Publication number
CA2640743C
CA2640743C CA2640743A CA2640743A CA2640743C CA 2640743 C CA2640743 C CA 2640743C CA 2640743 A CA2640743 A CA 2640743A CA 2640743 A CA2640743 A CA 2640743A CA 2640743 C CA2640743 C CA 2640743C
Authority
CA
Canada
Prior art keywords
microspheres
pharmaceutical composition
egf
group
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2640743A
Other languages
English (en)
French (fr)
Other versions
CA2640743A1 (en
Inventor
Blas Yamir Betancourt Rodriguez
Vivian Maria Saez Martinez
Rolando Paez Meireles
Jorge Amador Berlanga Acosta
Jose Angel Ramon Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Genetic Engineering and Biotechnology
Original Assignee
Center for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2640743(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Center for Genetic Engineering and Biotechnology filed Critical Center for Genetic Engineering and Biotechnology
Publication of CA2640743A1 publication Critical patent/CA2640743A1/en
Application granted granted Critical
Publication of CA2640743C publication Critical patent/CA2640743C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2640743A 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic limb amputation Active CA2640743C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU2006-0021 2006-01-31
PCT/CU2007/000002 WO2007087759A2 (es) 2006-01-31 2007-01-29 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Publications (2)

Publication Number Publication Date
CA2640743A1 CA2640743A1 (en) 2007-08-09
CA2640743C true CA2640743C (en) 2012-05-15

Family

ID=38185604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2640743A Active CA2640743C (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic limb amputation

Country Status (24)

Country Link
US (1) US8741848B2 (enExample)
EP (1) EP1987817B1 (enExample)
JP (1) JP5219841B2 (enExample)
KR (1) KR101401273B1 (enExample)
CN (2) CN103933552A (enExample)
AR (1) AR059234A1 (enExample)
AT (1) ATE437631T1 (enExample)
AU (1) AU2007211753B2 (enExample)
BR (1) BRPI0707395A2 (enExample)
CA (1) CA2640743C (enExample)
CU (1) CU23388B6 (enExample)
CY (1) CY1109513T1 (enExample)
DE (1) DE602007001786D1 (enExample)
DK (1) DK1987817T3 (enExample)
ES (1) ES2330688T3 (enExample)
HK (1) HK1198743A1 (enExample)
MY (1) MY143742A (enExample)
PL (1) PL1987817T3 (enExample)
PT (1) PT1987817E (enExample)
RU (1) RU2426528C2 (enExample)
SG (1) SG169366A1 (enExample)
SI (1) SI1987817T1 (enExample)
WO (1) WO2007087759A2 (enExample)
ZA (1) ZA200806648B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
RU2351334C1 (ru) * 2007-12-04 2009-04-10 Георгий Кимович Золоев Способ лечения хронической ишемии нижних конечностей ii б - iv степени
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
RU2421221C1 (ru) * 2010-03-22 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения критической ишемии нижних конечностей различного генеза
RU2425675C1 (ru) * 2010-05-25 2011-08-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения больных с нейропатической и нейроишемической формами синдрома "диабетическая стопа"
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX389934B (es) * 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
KR920700691A (ko) 1989-04-04 1992-08-10 존.에프.맥인티리 상처부위, 절개부위, 찰과상 부위에 치료제의 투여에 대한 리포좀(liposomes)의 용도
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JPH04501123A (ja) 1989-08-01 1992-02-27 ザ　ユニヴァーシティ　オブ　ミシガン 脱水／水補給リポソームに被嚢されたペプチド／タンパク質の局所送達
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
CA2251129A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
AU713276B2 (en) * 1996-05-23 1999-11-25 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
EP2316490A3 (en) * 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
CN100571773C (zh) 2002-03-12 2009-12-23 生物键有限公司 采用表皮生长因子治疗皮肤伤口的方法和组合物
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
ZA200806648B (en) 2009-05-27
SG169366A1 (en) 2011-03-30
PT1987817E (pt) 2009-10-26
BRPI0707395A2 (pt) 2011-05-03
US20090220608A1 (en) 2009-09-03
RU2008135354A (ru) 2010-03-10
SI1987817T1 (sl) 2009-12-31
JP2009525288A (ja) 2009-07-09
AU2007211753A1 (en) 2007-08-09
US8741848B2 (en) 2014-06-03
CA2640743A1 (en) 2007-08-09
RU2426528C2 (ru) 2011-08-20
CY1109513T1 (el) 2014-08-13
KR101401273B1 (ko) 2014-05-29
EP1987817B1 (en) 2009-07-29
ATE437631T1 (de) 2009-08-15
MY143742A (en) 2011-07-15
DK1987817T3 (da) 2009-11-30
WO2007087759A3 (es) 2007-09-20
EP1987817A2 (en) 2008-11-05
PL1987817T3 (pl) 2010-01-29
CU23388B6 (es) 2009-07-16
KR20080096804A (ko) 2008-11-03
JP5219841B2 (ja) 2013-06-26
WO2007087759A2 (es) 2007-08-09
AU2007211753B2 (en) 2012-03-01
DE602007001786D1 (de) 2009-09-10
AR059234A1 (es) 2008-03-19
HK1198743A1 (en) 2015-06-05
CN101400338A (zh) 2009-04-01
ES2330688T3 (es) 2009-12-14
CN103933552A (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
AU2007211753B2 (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
Pachuau Recent developments in novel drug delivery systems for wound healing
Jiang et al. Dual delivery of chlorhexidine and platelet-derived growth factor-BB for enhanced wound healing and infection control
DK2398488T3 (en) DEPOT SYSTEM INCLUDING GLATIR FRAME ACETATE
US20200197286A1 (en) Soluble microneedle for delivering proteins or peptides
US20220331492A1 (en) Composition and method for controlled drug release from a tissue
RU2662097C2 (ru) Липидные наночастицы для ранозаживления
Wassif et al. Recent advances in the local drug delivery systems for diabetic wound healing: A comprehensive review
CN101198348A (zh) 骨形态发生蛋白制剂
AU2006331223B2 (en) Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
Umeki et al. Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release
MX2008009943A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
HK1130681A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
TW201714610A (zh) 蛋白質或肽傳遞用的可溶性微針
EP2737895A1 (en) Microparticles with EGF, method of preparation and use
JP2001316282A (ja) 生理活性ペプチド含有コラーゲン成形体及びその製法
US20220211683A1 (en) Novel material for skin wound closure and scar prevention
Eilleia et al. Examining insulin adsorption onto mesoporous silica microparticles for oral delivery
WO1996026716A1 (en) Elcatonin controlled release microsphere formulation for treatment of osteoporosis
Hrynyk Enhanced burn wound healing through controlled and sustained delivery of bioactive insulin from alginate sponge dressings
US20160256565A1 (en) Composite bioabsorbable barrier membranes with sustained dual drug delivery for tissue engineering and guided tissue regeneration

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250129

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250129

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260312